| Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double … JS Heier, AM Khanani, CQ Ruiz, K Basu, PJ Ferrone, C Brittain, ... The Lancet 399 (10326), 729-740, 2022 | 416 | 2022 |
| Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two … CC Wykoff, F Abreu, AP Adamis, K Basu, DA Eichenbaum, Z Haskova, ... The Lancet 399 (10326), 741-755, 2022 | 348 | 2022 |
| Heterozygous mutations of the kinesin KIF21A in congenital fibrosis of the extraocular muscles type 1 (CFEOM1) K Yamada, C Andrews, WM Chan, CA McKeown, A Magli, ... Nature genetics 35 (4), 318-321, 2003 | 308 | 2003 |
| Apremilast for Behçet’s syndrome—a phase 2, placebo-controlled study G Hatemi, M Melikoglu, R Tunc, C Korkmaz, B Turgut Ozturk, C Mat, ... New England Journal of Medicine 372 (16), 1510-1518, 2015 | 252 | 2015 |
| Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness BT Ozturk, B Bozkurt, H Kerimoglu, M Okka, U Kamis, K Gunduz Molecular vision 15, 1906, 2009 | 161 | 2009 |
| Identification of KIF21A mutations as a rare cause of congenital fibrosis of the extraocular muscles type 3 (CFEOM3) K Yamada, WM Chan, C Andrews, TM Bosley, EC Sener, JT Zwaan, ... Investigative ophthalmology & visual science 45 (7), 2218-2223, 2004 | 118 | 2004 |
| Demographic and clinical characteristics of uveitis in Turkey: the first national registry report FN Yalçındağ, PC Özdal, Y Özyazgan, F Batıoğlu, I Tugal-Tutkun, ... Ocular immunology and inflammation 26 (1), 17-26, 2018 | 108 | 2018 |
| Kentsel açık ve yeşil alan sistemi oluşturulması: Kayseri kent bölümü örneği B Öztürk Fen Bilimleri Enstitüsü, 2004 | 86 | 2004 |
| Topical anesthetic abuse keratopathy: a commonly overlooked health care problem A Yagci, B Bozkurt, S Egrilmez, M Palamar, BT Ozturk, H Pekel Cornea 30 (5), 571-575, 2011 | 85 | 2011 |
| Effect of altered eating habits and periods during Ramadan fasting on intraocular pressure, tear secretion, corneal and anterior chamber parameters H Kerimoglu, B Ozturk, K Gunduz, B Bozkurt, U Kamis, M Okka Eye 24 (1), 97-100, 2010 | 74 | 2010 |
| A truncating mutation in SERPINB6 is associated with autosomal-recessive nonsyndromic sensorineural hearing loss A Sırmacı, S Erbek, J Price, M Huang, D Duman, FB Cengiz, G Bademci, ... The American Journal of Human Genetics 86 (5), 797-804, 2010 | 72 | 2010 |
| A clinically variant fibrosis syndrome in a Turkish family maps to the CFEOM1 locus on chromosome 12 EC Sener, BA Lee, B Turgut, AN Akarsu, EC Engle Archives of ophthalmology 118 (8), 1090-1097, 2000 | 66 | 2000 |
| A preliminary trial to determine whether prevention of dark adaptation affects the course of early diabetic retinopathy GB Arden, MK Gündüz, A Kurtenbach, M Völker, E Zrenner, SB Gündüz, ... Eye 24 (7), 1149-1155, 2010 | 63 | 2010 |
| Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema BT Ozturk, H Kerimoglu, B Bozkurt, S Okudan Journal of Ocular Pharmacology and Therapeutics 27 (4), 373-377, 2011 | 62 | 2011 |
| Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye B Bakbak, BT Ozturk, S Gonul, M Yilmaz, S Gedik Journal of ocular pharmacology and therapeutics 29 (8), 728-732, 2013 | 57 | 2013 |
| Glucose regulation influences treatment outcome in ranibizumab treatment for diabetic macular edema BT Ozturk, H Kerimoglu, M Adam, K Gunduz, S Okudan Journal of Diabetes and its Complications 25 (5), 298-302, 2011 | 46 | 2011 |
| Ocular changes in primary hypothyroidism BT Ozturk, H Kerimoglu, O Dikbas, H Pekel, MS Gonen BMC research notes 2, 1-5, 2009 | 45 | 2009 |
| Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? H Kerimoglu, BT Ozturk, B Bozkurt, M Okka, S Okudan Acta ophthalmologica 89 (2), 138-142, 2011 | 39 | 2011 |
| Faricimab treat-and-extend for diabetic macular edema: Two-year results from the randomized Phase 3 YOSEMITE and RHINE trials TY Wong, Z Haskova, K Asik, CR Baumal, KG Csaky, N Eter, JA Ives, ... Ophthalmology 131 (6), 708-723, 2024 | 31 | 2024 |
| TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2 AM Khanani, A Kotecha, A Chang, SJ Chen, Y Chen, R Guymer, JS Heier, ... Ophthalmology, 2024 | 31 | 2024 |
